Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL208144 | 0.83 | CA1 (0.40) | CA1CA2 | |
| Succinic Acid SCHEMBL506729 | 0.83 | NOTUM (0.37) | CA1CA2MAOAMAOB | |
| Hydrochloric Acid SCHEMBL506406 | 0.82 | PARP1 (0.39) | CA1CA2 | |
| Water SCHEMBL16428036 | 0.82 | CA1 (0.43) | CA1CA2 | |
| Bromide SCHEMBL16698664 | 0.82 | CA1 (0.39) | CA1CA2 | |
| Water SCHEMBL16428037 | 0.82 | CA1 (0.43) | CA1CA2 | |
| SCHEMBL27693919 | 0.82 | CA1 (0.39) | CA1CA2 | |
| Hydrochloric Acid SCHEMBL28783882 | 0.80 | CA1 (0.42) | CA1CA2 | |
| Trifluoroacetic Acid SCHEMBL25247629 | 0.74 | — | — | |
| Trifluoroacetic Acid SCHEMBL31674669 | 0.71 | CES1 (0.37) | CES1KDM1ADPP8DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | CNR2, GRIN2C, GRIN2B | CES1 842/4885KDM1A 1201/4885CA1 1515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.